logo
Plus   Neg
Share
Email

Neurocrine Biosciences, Idorsia Amend Option Agreement To License ACT-709478

Neurocrine Biosciences, Inc. (NBIX) and Idorsia Ltd. have amended their 2019 agreement granting Neurocrine Biosciences an option to license ACT-709478, a potent brain penetrating T-type calcium channel blocker in development for epilepsy.

Upon Investigational New Drug application acceptance by the FDA, expected in mid-2020, Neurocrine Biosciences will have 30 days to exercise the option to license ACT-709478. If the option is exercised by Neurocrine Biosciences, Idorsia will receive an upfront payment of $45 million. Idorsia may also receive up to $365 million in additional development and regulatory milestone payments.

Also, Neurocrine Biosciences will provide an incremental $7 million in funding to Idorsia as part of the research collaboration.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apple is tracking iPhones that were stolen from its retail stores in recent days during the civil unrest, according to reports citing a warning message popping up on the stolen iPhones. Four current and former senior executives from two major broiler chicken producers, including Pilgrim's Pride CEO Jayson Penn, have been indicted for price fixing. Kezar Life Sciences, Inc. (KZR) - Shares of the clinical-stage biotechnology company soared nearly 80% after closing bell. The company's lead drug candidate is KZR-616, a selective inhibitor of immunoproteasome that plays a crucial role in the immune system. KZR-616 is under a phase Ib/II study in...
RELATED NEWS
Follow RTT